Shares of Gossamer Bio Inc. (GOSS) are surging 5.30% in pre-market trading on Monday, following a bullish move by Oppenheimer analysts. The investment firm has raised its price target for Gossamer Bio from $9 to $12, signaling increased confidence in the company's future prospects.

This significant boost in the price target represents a vote of confidence in Gossamer Bio's business model and growth potential. Oppenheimer's decision to raise the target price by 33% suggests that the firm believes Gossamer Bio's stock is undervalued at its current levels and has room for substantial growth.

Investors are reacting positively to this news, as evidenced by the pre-market rally. The increased price target could attract more attention from both institutional and retail investors, potentially driving further gains in the stock. As the market opens, it will be interesting to see if Gossamer Bio can maintain this momentum throughout the trading session.